MDT-AP-3254
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 3.6
- sex
- M
- new_clusters
- S2
- umap1_2d
- 0.467471507
- umap2_2d
- -9.57290156
- umap1_3d
- -4.286170071
- umap2_3d
- -1.343323501
- umap3_3d
- 5.721279334
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- MYC_TARGETS_V1+0.490
- G2M_CHECKPOINT+0.460
- E2F_TARGETS+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.430
- PROTEIN_SECRETION+0.310
- MTORC1_SIGNALING+0.290
- MITOTIC_SPINDLE+0.270
- ANDROGEN_RESPONSE+0.170
- SPERMATOGENESIS+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- IL6_JAK_STAT3_SIGNALING-0.470
- INFLAMMATORY_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.410
- COMPLEMENT-0.410
- TNFA_SIGNALING_VIA_NFKB-0.410
- COAGULATION-0.400
- INTERFERON_ALPHA_RESPONSE-0.380
- MYOGENESIS-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.911 |
| 2 | 5af838ac-ab79-41c0-81fb-168cf9b1cf50 | — | — | 0.911 |
| 3 | SRR5088887 | — | — | 0.908 |
| 4 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.906 |
| 5 | TCGA-AR-A24K-01A-11R-A169-07 | — | B | 0.901 |
| 6 | SRR650141 | — | — | 0.898 |
| 7 | SRR4195671 | — | — | 0.892 |
| 8 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.891 |
| 9 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.886 |
| 10 | MDT-AP-0188 | Med | Medulloblastoma | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.430 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |